KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer.

Matthieu Delaye, Adrien Rousseau, Mélanie Try, Christophe Massard, Luca Campedel, Marc Hilmi, Corinne Bagnis

Cancer Med 12(3) 3172-3175

PMID36156460
PMCIDPMC9939176
DOI10.1002/cam4.5171
发表日期2022-09-26
入排依据:This record is a methodological analysis of patient exclusion criteria across multiple phase 3 oncology trials, not a report of survival or efficacy outcomes from a specific randomized controlled trial. While the publication metadata indicates it is a Phase III/Randomized Controlled Trial journal article, the content is a survey of trial protocols (ClinicalTrials.gov) focusing on renal exclusion criteria, not trial results. It therefore lacks the required outcome signal (survival, progression, etc.) for inclusion.
摘要

摘要

The objective of this study was to determine the proportion of phase 3 clinical trials investigating a systemic therapy for patients with prostate, breast, lung, or colorectal cancer that excluded patients with Chronic Kidney Disease (CKD) and the exclusion criteria chosen, if any. A search was conducted using the ClinicalTrials.gov database to identify eligible studies. Of the 268 included trials, 185 (69%) had at least one renal exclusion criteria. Of these 185 trials, 116 (63%) had an undefined exclusion criterion. Only disease site was associated with exclusion of patients with CKD in the univariate analysis, but no factors in the multivariate analysis. There are several potential barriers to including patients with CKD in clinical trials. Nevertheless, solutions can be proposed to allow the inclusion of these patients. This would allow them to access to innovative therapeutic strategies, but also allow a better applicability of trial results to this patient population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。